Home » PHASE I ANTICANCER COMPOUND TRIAL LAUNCHED
PHASE I ANTICANCER COMPOUND TRIAL LAUNCHED
July 26, 2005
Exelixis has initiated a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of XL820, a novel, orally administered, small molecule anticancer compound. XL820 is a spectrum selective kinase inhibitor, which simultaneously inhibits the receptor tyrosine kinases (RTKs) VEGF, KIT, and PDGF, all of which are clinically validated targets implicated in a variety of human cancers.
The Phase I clinical trial is an open-label, single and repeat dose-escalation study, and will be conducted in patients with solid tumors for whom there are no available therapies known to prolong survival.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct